Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline + vonoprazan dual therapy vs bismuth-containing quadruple therapy for H. pylori eradication
ChiCTR2600122517Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of minocycline and vonoprazan in Helicobacter pylori infection (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: Eradication rate of Helicobacter pylori infection. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
minocyclinevonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2600122517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122517.